Drug solubilization strategies: Applying nanoparticulate formulation and solid dispersion approaches in drug development

American Pharmaceutical Review

Volumn 13, Issue 1, 2010, Pages 12-21

  Timpe, Carsten ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; CILOSTAZOL; EVEROLIMUS; EXCIPIENT; FENOFIBRATE; GRISEOFULVIN; LOPINAVIR PLUS RITONAVIR; MEGESTROL ACETATE; NABILONE; NANOCRYSTAL; NANOPARTICLE; PALIPERIDONE; RAPAMYCIN; RITONAVIR; TACROLIMUS;

ARTICLE; DISPERSION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; PRECIPITATION;

EID: 77649208510     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. C. Timpe, Strategies for Formulation Development of Poorly Water-Soluble Drug Candidates - a Recent Perspective, Am.Pharm.Review, Vol. 10(3). 2007,104-109
2. J. Breitenbach, Drug delivery, a tool for imorived products: Kaletra® tablets, Presentation at Ìnforma Life Sciences Conference 'Strategies to Enhance Solubility and Drug Absorption', December 2007, Brussels
3. D. Bikiaris et al. Investigation of the release mechanism of a sparingly water-soluble drug rom solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions, Eur.J.Pharm.Biopharm 66 (2007) 334-347
4. ATM Serajuddin, Solid dispersion of poorly water-soluble drug: early promises, subsequent problems, and recent breakthroughs, .Pharm. Sci (1999), 88: 1058-1066
5. A. Fahr, X.Liu, Drug delivery strategies for poorly soluble drugs, Expert Opin. Drug Deliv. (2007) 4(4): 403-416
6. C. Timpe, A. Diederich, O. Kalb, A novel solvent-based fluidized bed wet granulation process for solid dispersions, Am.Pharm.Review, Vol. 11(4). 2008, 75-81
7. J. Jinno, N. Kamada, M. Miyake, K. Yamada, T.Mukai, M. Odomi, H. Toguchi, G.G. Liversidge, K. Higaki, T. Kimura, Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs, J. Control. Release 111 (1-2) (2006) 56-64
8. R.H. Müller, K. Peters, Nanosuspensions for the formulation of poorly soluble drugs I: Preparation by a size-reduction technique, Int.J.Pharma. 160 (1998) 229-237
9. E. Karavas, E. Georgarakis, M.P.Sigalas, K. Avgoustakis, D.Bikiaris , Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions, European Journal of Pharmaceutics and Biopharmaceutics 66 (2007) 334-347.
10. D.Hörter, J.B. Dressmann ,Influence of physicochemical properties on dissolution of drugs in the, gastrointestinal tract, Advanced Drug Delivery Reviews 25 (1997) 3-14.
11. M. Wunderlich, R. Becker, Th. Bock, R.Brickl, W., J.Dressman, Predicting drug formulation effects on the precipitation of a poorly soluble basic drug in the small intestine, J. Pharm. Pharmacol.,2004,vol.56,no1,.43-51
12. K. Miyazaki, The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled release formulations, Eur.J.Pharm. Sciences 26 (2005) 1-84.
13. G.G. Liversidge, K.C. Cundy, J. Bishop, D. Czekai, 1991.Surface modified drug nanoparticles, US Patent No. 5145684.
14. G.C. Liversidge, P. Conzentino, Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats, Int. J. Pharm. 125 (1995) 309-313.
15. G.C. Liversidge, K.C. Cundy, Particle size reduction for absolute oral bioavailability of nanocrystalline danazole in beagle dogs, Int. J. Pharm. 127 (1995) 91-97.
16. R.H. Mueller, C. Jacobs, O. Kayser, Advanced Drug Delivery Reviews 47 (2001) 3-19
17. Z. Deng et al., Understanding a relaxation behavior in a nanoparticlesuspension for drug delivery applications, International Journal of Pharmaceutics 351 (2008) 236-243
18. L. Lindfors et al., Amorphous Drug Nanosuspensions. 1. Inhibition of Ostwald Ripening, Langmuir 2006, 22, 906-910
19. J. Lee , J.-Y. Choi, C.H. Park, Characteristics of polymers enabling nanocomminution of water-insoluble drugs, Int. J. Pharm. 355 (2008) 328-336
20. B. Van Eerdenbrugh, G. Van den Mooter, P. Augustijns, Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products, Int. J. Pharm. 364 (2008) 64-75
21. R.H. Müller, J. Möschwitzer, F.N. Bushrab, Manufacturing of nanoparticles by milling and homogenization techniques. In: R.B. Gupta, U.B. Kompella (ed.), Nanoparticle Technology for Drug Delivery, Drugs and the Pharmaceutical Sciences, vol. 159, Taylor & Francis Group, LLC (New York), 21-51
22. 22B. Van Eerdenbrugh, L. Froyen, J. Van Humbeeck, J. A. Martens, P. Augustijnsa, G. Van Den Mooter, Alternative matrix formers for nanosuspension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion, Eur.J. Pharm. Sciences 35 (2008) 344-353
23. Dong Z, Chatterji A, Sandhu H, Choi DS, Chokshi H, Shah N. 2008. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent coprecipitation.Int J Pharm 335:141-149
24. T. Vasconcelos, Solid dispersions as strategy to improve solubility/dissolution of poorly soluble drugs (Presentation), 2nd Enhanced Solubility and Bioavailability IQPC Conference, Frankfurt 2009
25. J. Breitenbach et al., Confocal Raman Spectroscopy: Analytical Approach to Solid Dispersions and Mapping of Drugs, Pharm. Res. 16: 1109- 1113 (1999)
26. L. Yu, Amorphous pharmaceutical solids: preparation, characterization and stabilization, Adv. Drug Deliv. Rev., Vol. 48 (1), 2001, 27-42